替加色罗:旧药新用
本文综述替加色罗作为5-HT4激动剂治疗便秘型肠易激综合征(IBS-C)和慢性特发性便秘(CIC)的药代动力学、生理学、临床及安全性数据,回顾其2002年与2004年首次获批、2007年因心血管不良事件撤市、2019年4月以更严格标签重新获批用于65岁以下无心脏病或额外心血管危险因素的女性IBS-C患者的监管历程,并讨论其未来应用。
要点
- 替加色罗是5-HT4激动剂,有大量临床前和临床证据支持其调节管腔胃肠道感觉运动功能。
- 替加色罗2002年和2004年分别获美国食品药品监督管理局批准用于IBS-C和CIC,2007年因心血管不良事件担忧撤市。
- 2019年4月替加色罗重新获批用于IBS-C,标签限制于65岁以下无心脏病或额外心血管危险因素的女性。
核心结论
- 替加色罗在调节管腔胃肠道感觉运动功能方面有大量临床前和临床证据支持其有益作用。
- 替加色罗经历2002年和2004年获批、2007年撤市、2019年4月以更严格标签重新获批用于IBS-C的监管历程。
- 本文讨论替加色罗在便秘性疾病治疗中的未来及在脑-肠互动相关其他疾病中的潜在作用。
研究设计与样本
- 综述总结了替加色罗的监管历程及过去20年生成的药代动力学、生理学、临床和安全性数据。
主要发现
- 替加色罗2002年获美国食品药品监督管理局批准用于IBS-C,2004年获批用于CIC。
- 替加色罗2007年因心血管不良事件担忧撤市。
- 2019年4月替加色罗重新获批用于IBS-C,标签限制于65岁以下无心脏病或额外心血管危险因素的女性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are common gastrointestinal disorders imposing considerable impact on the quality of life and well-being of affected individuals. A paucity of evidence-based treatment options exist for CIC and IBS-C sufferers. Tegaserod, a 5-HT4 agonist, has a substantial body of preclinical and clinical study evidence to support its beneficial role in modulating sensorimotor function of the luminal gastrointestinal tract. Tegaserod was first approved for use by the U.S. Food and Drug Administration for the management of IBS-C and CIC in 2002 and 2004, respectively. Tegaserod enjoyed a successful uptake in the management of these disorders during its first several years of availability in the United States, but was later withdrawn from the market in 2007 over concerns related to adverse cardiovascular events. Since then, additional safety data has been generated, and following a resubmission and review by the Food and Drug Administration, in April 2019, tegaserod was once again approved for use in IBS-C under a more restricted labeling, confining use to women under 65 years of age without heart disease or additional cardiovascular risk factors. This review summarizes the regulatory journey of tegaserod and details the existing pharmacokinetic, physiologic, clinical, and safety data of tegaserod generated over the last 2 decades. The discussion also examines the future of tegaserod in the treatment of these constipation disorders, as well as its potential role in other related disorders of brain-gut interaction.
引用
- Sayuk GS, Tack J. Tegaserod: What's Old Is New Again. Clin Gastroenterol Hepatol. 2022. PMID: 35123085. doi:10.1016/j.cgh.2022.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。